The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer

November 11, 2019 updated by: Arne Astrup, University of Copenhagen

The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer

The study is based on a master thesis which showed that 72% of patients with head and neck cancer admitted to a Danish hospital (Rigshospitalet, Copenhagen) developed refeeding syndrome after admission.

Refeeding syndrome is characterized by a decrease in plasma phosphate levels, which develops after the reintroduction of an adequate food intake after a longer period of starvation or semi-starvation. This normally happens within 7 days after reintroduction of food.

The aim of this study is to minimize the incidence of refeeding syndrome in this group of patients by reintroducing food slowly and by providing a diet low in sodium and high in slowly absorbed carbohydrates as a prevention diet (i.e. given before a potential decrease in plasma phosphate levels appear). Both patients that eat normally, patients with eating tubes and patients with central vein catheters are included in the study, but the data will be evaluated both together and separately.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A large weight loss as a result of a longer period (>30 days) of starvation or semi-starvation will result in a metabolic adaptation to the decreased food intake. To prevent the degradation of muscle mass into gluco- and ketogenic amino acids to be used for energy production, a shift from gluconeogenesis to lipolysis occurs. Lipids therefore become the primary energy fuel, and the body adapts to use ketone bodies instead of glucose. The reduction in glucose metabolism results in a decreased need for amino acids for use in gluconeogenesis. This means that less amino acids are needed for gluconeogenesis and therefore important muscle mass is preserved. At the same time as the lipid stores are degraded, an intracellular depletion of phosphate, potassium and magnesium occurs. The serum levels of these electrolytes stay within the normal range as long as the body is in the adaptive starvation state. A too quick reintroduction of food to the body will result in a major glucose-induced increase in insulin secretion that will stimulate the transport of glucose, phosphate, potassium and magnesium from plasma into the cells. Because the extracellular blood volume is much smaller than the intracellular, an influx of these electrolytes to the intracellular space will result in a quick and large decrease in the plasma levels. Likewise, an influx of glucose means that it again can enter the glucolysis, and the need for phosphate and the co-factor thiamine, for the production of ATP, will increase. The increased production of adenosine triphosphate (ATP) will activate membrane pumps and reestablish the membrane potential. This means that sodium will be transported from the large intracellular space to the small extracellular, with subsequent fluid retention and edema formation.

Therefore a slowly introduced diet low in sodium and high in slowly absorbed carbohydrates might prevent the development of refeeding syndrome.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen ø, Denmark, 2100
        • Rigshospitalet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • authoritative
  • written consent
  • suspected of or diagnosed with head and neck cancer
  • Increased risk of Refeeding syndrome, defined by one of the below:
  • A-score of 1 in the Nutritional Risk Screening 2002 (NRS 2002)
  • high levels of alcohol consumption (men>168g alcohol/week corresponding to approximately 14 units, women>84g alcohol/week corresponding to approximately 7 units)
  • anamnesis with prior radiation therapy
  • Head and neck pain that require pain management or inhibits food intake
  • the presence of problems with eating that are so serious that the food intake is inhibited

Exclusion Criteria:

  • minor or declared incapable of managing own affairs
  • patients that are incapable of understanding and communicating in Danish
  • patients with dementia
  • if the patient is not diagnosed with head and neck cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Low sodium diet
Low sodium diet
NO_INTERVENTION: Control
Standard diet regime

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurence of Refeeding events
Time Frame: daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7
Measured by a decrease in plasma phosphate levels.
daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of infections
Time Frame: daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7
Measured by infection events recorded in the medical journal.
daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7
Length of stay
Time Frame: Number of days from admission until discharge from the hospital, assessed up to 6 month
Measured by number of days in the hospital
Number of days from admission until discharge from the hospital, assessed up to 6 month
Amount of days admitted to a Intensive-care unit
Time Frame: Number of days from admission until discharge from the Intensive-care unit, assessed up to 6 month
Measured by number of days in the intensive-care unit
Number of days from admission until discharge from the Intensive-care unit, assessed up to 6 month
Other complications than infections
Time Frame: daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7
Measured by thrombosis events and other complications recorded in the medical journal
daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nutritional status
Time Frame: daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7
Measured by changes in plasma cobalamin levels/vitamin B12 levels (pmol/L), plasma iron levels (μmol/L), plasma ferritin levels (μg/L), mean cell volume (MCV) (fL), plasma albumin levels (μmol/L), plasma alanine aminotransferase levels (ALAT) (U/L), plasma coagulation factors II, VII, X levels (INR), plasma c-reactive protein levels (nmol/L), hemoglobin levels (Hgb) (mmol/L), plasma sodium levels (mmol/L), plasma potassium levels (mmol/L), plasma creatinine levels (μmol/L), plasma carbamide levels (mmol/L), plasma folate levels (nmol/L), plasma zink levels (μmol/L), plasma magnesium levels (mmol/L) and plasma selenium levels (μg/L).
daily, starting from day of admission and until day 7 of the treatment period or until discharge from the hospital if before day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jens R. Andersen, MD, lektor, University of Copenhagen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 1, 2013

Primary Completion (ACTUAL)

February 1, 2014

Study Completion (ACTUAL)

February 1, 2014

Study Registration Dates

First Submitted

April 22, 2013

First Submitted That Met QC Criteria

May 2, 2013

First Posted (ESTIMATE)

May 3, 2013

Study Record Updates

Last Update Posted (ACTUAL)

November 13, 2019

Last Update Submitted That Met QC Criteria

November 11, 2019

Last Verified

November 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Refeeding Syndrome

Clinical Trials on Low sodium diet

Subscribe